The authors suggested that VISTA expression is a compensatory pathway limiting efficiency of ipilimumab therapy of prostate cancer (282), and targeting of VISTA on TAMs can be suggested as next therapeutic approach to develop. This evidence concerns the gene VSIR and Familial prostate cancer.